Canada Markets closed
  • S&P/TSX

    -206.31 (-1.19%)
  • S&P 500

    -16.72 (-0.46%)
  • DOW

    -271.73 (-0.91%)

    +0.0015 (+0.1904%)

    -0.42 (-0.93%)

    +42.64 (+0.17%)
  • CMC Crypto 200

    +19.65 (+5.39%)

    +5.30 (+0.30%)
  • RUSSELL 2000

    -35.45 (-1.91%)
  • 10-Yr Bond

    +0.0020 (+0.24%)
  • NASDAQ futures

    +104.50 (+0.85%)

    -0.27 (-1.30%)
  • FTSE

    -101.39 (-1.59%)
  • NIKKEI 225

    +390.84 (+1.48%)

    0.0000 (0.00%)

Peanut Allergy R&D Pipeline Analysis Report, Q4 2020 -

·4 min read

The "Peanut Allergy R&D Pipeline Analysis Report, Q4 2020" report has been added to's offering.

This review describes the pipeline of drugs under development for Peanut Allergy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Peanut Allergy Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Peanut Allergy disease overview, Peanut Allergy types, Peanut Allergy symptoms, causes, and FDA/EMA approved treatment options.

Peanut Allergy Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Peanut Allergy indication. The report presents near-term and long-term pipeline development trends and potential insights.

Peanut Allergy Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 25 companies. Business profiles and contact details of the companies actively perusing Peanut Allergy pipeline are assessed.

Peanut Allergy R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Peanut Allergy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Peanut Allergy companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Peanut Allergy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Peanut Allergy Pipeline Market News and Developments during 2020

The Peanut Allergy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Peanut Allergy Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Scope and Coverage

  • Peanut Allergy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

  • Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

  • Company-company partnerships, company-institute partnerships, and investment details of companies are included

  • 25 companies are included

  • Disease overview, Pipeline trends, market analysis, and other developments

  • Potential licensing/new business opportunities in Peanut Allergy pipeline market


  • Global coverage of companies and pipeline agents

  • 2020 Trends, market analysis, and developments

  • Potential growth opportunities

  • Comprehensive details of drug candidates

Key Topics Covered:

1. Table of Contents

1.1 List of Tables

1.2 List of Figures

2. Peanut Allergy Pipeline Trends and Insights

2.1 Dominant Phase type of Peanut Allergy Pipeline, 2020

2.2 Most focused Mechanism of Action in Peanut Allergy Pipeline

2.3 Leading type of Route of Administration during 2020

2.4 Proportion of New Molecular Entities in Peanut Allergy pipeline

2.5 Active Companies Developing Peanut Allergy pipeline

3. Peanut Allergy Disease Types, Symptoms, Causes, and Available Treatment Options

3.1 Disease Overview

3.2 Types

3.3 Symptoms

3.4 Approved Treatment Options

4. Peanut Allergy Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts

  • Adverum Biotechnologies Inc

  • Aimmune Therapeutics Inc

  • Allakos Inc

  • Allergy Therapeutics Plc

  • AnaptysBio Inc

  • Aravax Pty Ltd

  • ASIT Biotech SA

  • BioLingus AG

  • BlueWillow Biologics Inc

  • Cambridge Allergy Ltd

  • Cour Pharmaceuticals Development Co Inc

  • DBV Technologies SA

  • F. Hoffmann-La Roche Ltd

  • HAL Allergy BV

  • Immunomic Therapeutics Inc

  • Inimmune Corp

  • InnoUp Farma SL

  • Moonlight Therapeutics Inc

  • ProTA Therapeutics Pty Ltd

  • Regeneron Pharmaceuticals Inc

  • Sanofi

  • Sementis Ltd

  • Vedanta Biosciences Inc

  • Virtici LLC


5. Peanut Allergy Pipeline Drug Profiles

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

6. Peanut Allergy Pipeline Market News and Developments during 2020

7. Appendix

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900